Status:

COMPLETED

Residual Vein Thrombosis Establishes the Optimal Duration of Oral Anticoagulants

Lead Sponsor:

Azienda Ospedaliera Universitaria Policlinico

Conditions:

Deep Vein Thrombosis

Eligibility:

All Genders

18+ years

Phase:

PHASE4

Brief Summary

ABSTRACT Background The optimal duration of oral anticoagulant treatment in patients with idiopathic venous thromboembolism is still uncertain . The present study addressed the possible role of the Re...

Detailed Description

INTRODUCTION Long-term anticoagulant treatment with adjusted doses of vitamin K antagonists is highly effective in preventing recurrent events after a first episode of unprovoked Venous ThromboEmbolis...

Eligibility Criteria

Inclusion

  • First episode of unprovoked and provoked proximal DVT of the lower limbs and treated for 3 month with oral anticoagulants

Exclusion

  • Active cancer,
  • Limited life expectancy,
  • Antiphospholipid antibody syndrome, or an other known thrombophilic status (such as antithrombin deficiency),
  • Serious liver disease,
  • Renal insufficiency (serum creatinine \> 2 mg/dL).

Key Trial Info

Start Date :

November 1 2003

Trial Type :

INTERVENTIONAL

End Date :

September 1 2006

Estimated Enrollment :

250 Patients enrolled

Trial Details

Trial ID

NCT00438230

Start Date

November 1 2003

End Date

September 1 2006

Last Update

February 22 2007

Active Locations (0)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 0 (0 locations)

No Results Found

We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.

Residual Vein Thrombosis Establishes the Optimal Duration of Oral Anticoagulants | DecenTrialz